News

Under the agreement, EpiTherapeutics will receive an upfront payment as well as funding of research activities. In addition, under certain conditions, EpiTherapeutics is eligible to receive milestone payments

Novartis said that the investment is part of an overall $500m commitment in local infrastructure and collaborative healthcare initiatives planned over a five-year period. The partnership addresses three

Letendre will be responsible for spearheading the clinical, regulatory, IP and strategic direction of the company. Based on data from a pilot proof of concept (POC) study in

Superabsorbent polymers are plastics with the capacity to absorb up to 500 times their own weight in liquid. Superabsorbent polymers are mainly used to make diapers. Adult incontinence

Shionogi Pharma and CIMA LABS filed the lawsuit in the US District Court for the District of Delaware. The product is the generic version of Orapred ODT, a

Under the alliance agreement Sanofi-aventis obtains a worldwide exclusive license to develop and commercialize the compounds As part of the research alliance, Sanofi-aventis will work together with Avila

The development candidate, RXI-109, is a self-delivering RNAi compound (sd-rxRNA) that will initially be evaluated for the reduction of dermal scarring in planned surgeries. RXi Pharma said that

The local distributors will sell the China-Biotics’ retail probiotics products through their distribution networks including malls, supermarkets and functional food stores adding approximately 30 new points of sale.

The novel combinations involve Merck Serono‘s MEK inhibitor MSC1936369B (also known as AS703026), Sanofi-aventis PI3K/mTOR inhibitor SAR245409 (also known as XL765) and class I PI3K inhibitor SAR245408 (also